SINCO PHARMA’s September 2026 Monthly Return Shows Stable Share Base and Full Public Float Compliance

Bulletin Express10-02

Sinco Pharmaceuticals Holdings Limited (SINCO PHARMA) filed its Monthly Return for the period ended 30 September 2026, confirming that the company’s share structure remained unchanged during the month.

Authorised and Issued Share Capital • Authorised capital stood at 10.00 billion ordinary shares with a par value of HKD 0.0001, representing HKD 1.00 million in registered share capital. • Issued share count held steady at 2.03 billion shares, identical to the previous month’s closing balance. • The company continues to hold zero treasury shares, indicating no buy-backs or cancellations.

Share Option Scheme Activity • The Share Option Scheme adopted on 26 May 2025 recorded no grants, exercises, cancellations or lapses in September. • No new funds were raised from option exercises, and 203.29 million shares remain available for future option grants under the scheme.

Public Float Status • SINCO PHARMA confirmed compliance with Hong Kong Main Board Rule 13.32D(1), maintaining at least the required 25 percent public float.

Other Equity Instruments • The filing reported no outstanding or new warrants, convertibles, Hong Kong depositary receipts, or other share-issuing agreements.

Overall, the September 2026 return underscores a steady capital structure for SINCO PHARMA, with no equity dilution or treasury share movements and full adherence to Hong Kong listing requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1140198649?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-02 17:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140198649","market":"hk","top_or_hot":-1,"title":"SINCO PHARMA’s September 2026 Monthly Return Shows Stable Share Base and Full Public Float Compliance","media":"Bulletin Express","content":"<p>Sinco Pharmaceuticals Holdings Limited (SINCO PHARMA) filed its Monthly Return for the period ended 30 September 2026, confirming that the company’s share structure remained unchanged during the month.</p>\n<p>Authorised and Issued Share Capital  \n• Authorised capital stood at 10.00 billion ordinary shares with a par value of HKD 0.0001, representing HKD 1.00 million in registered share capital.  \n• Issued share count held steady at 2.03 billion shares, identical to the previous month’s closing balance.  \n• The company continues to hold zero treasury shares, indicating no buy-backs or cancellations.</p>\n<p>Share Option Scheme Activity  \n• The Share Option Scheme adopted on 26 May 2025 recorded no grants, exercises, cancellations or lapses in September.  \n• No new funds were raised from option exercises, and 203.29 million shares remain available for future option grants under the scheme.</p>\n<p>Public Float Status  \n• SINCO PHARMA confirmed compliance with Hong Kong Main Board Rule 13.32D(1), maintaining at least the required 25 percent public float.</p>\n<p>Other Equity Instruments  \n• The filing reported no outstanding or new warrants, convertibles, Hong Kong depositary receipts, or other share-issuing agreements.</p>\n<p>Overall, the September 2026 return underscores a steady capital structure for SINCO PHARMA, with no equity dilution or treasury share movements and full adherence to Hong Kong listing requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SINCO PHARMA’s September 2026 Monthly Return Shows Stable Share Base and Full Public Float Compliance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSINCO PHARMA’s September 2026 Monthly Return Shows Stable Share Base and Full Public Float Compliance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-10-02 17:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sinco Pharmaceuticals Holdings Limited (SINCO PHARMA) filed its Monthly Return for the period ended 30 September 2026, confirming that the company’s share structure remained unchanged during the month.</p>\n<p>Authorised and Issued Share Capital  \n• Authorised capital stood at 10.00 billion ordinary shares with a par value of HKD 0.0001, representing HKD 1.00 million in registered share capital.  \n• Issued share count held steady at 2.03 billion shares, identical to the previous month’s closing balance.  \n• The company continues to hold zero treasury shares, indicating no buy-backs or cancellations.</p>\n<p>Share Option Scheme Activity  \n• The Share Option Scheme adopted on 26 May 2025 recorded no grants, exercises, cancellations or lapses in September.  \n• No new funds were raised from option exercises, and 203.29 million shares remain available for future option grants under the scheme.</p>\n<p>Public Float Status  \n• SINCO PHARMA confirmed compliance with Hong Kong Main Board Rule 13.32D(1), maintaining at least the required 25 percent public float.</p>\n<p>Other Equity Instruments  \n• The filing reported no outstanding or new warrants, convertibles, Hong Kong depositary receipts, or other share-issuing agreements.</p>\n<p>Overall, the September 2026 return underscores a steady capital structure for SINCO PHARMA, with no equity dilution or treasury share movements and full adherence to Hong Kong listing requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06833","symbol_name":"兴科蓉医药","start_time":0,"source_url":"","article_id":"1140198649","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140198649","pubTimestamp":1790932310,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sinco Pharmaceuticals Holdings Limited (SINCO PHARMA) filed its Monthly Return for the period ended 30 September 2026, confirming that the company’s share structure remained unchanged during the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06833":"兴科蓉医药"},"translate_title":"SINCO PHARMA 2026 年 9 月的月报表显示股票基础稳定，完全符合公众持股量要求","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06833":1},"content_text":"Sinco Pharmaceuticals Holdings Limited (SINCO PHARMA) filed its Monthly Return for the period ended 30 September 2026, confirming that the company’s share structure remained unchanged during the month.\nAuthorised and Issued Share Capital  \n• Authorised capital stood at 10.00 billion ordinary shares with a par value of HKD 0.0001, representing HKD 1.00 million in registered share capital.  \n• Issued share count held steady at 2.03 billion shares, identical to the previous month’s closing balance.  \n• The company continues to hold zero treasury shares, indicating no buy-backs or cancellations.\nShare Option Scheme Activity  \n• The Share Option Scheme adopted on 26 May 2025 recorded no grants, exercises, cancellations or lapses in September.  \n• No new funds were raised from option exercises, and 203.29 million shares remain available for future option grants under the scheme.\nPublic Float Status  \n• SINCO PHARMA confirmed compliance with Hong Kong Main Board Rule 13.32D(1), maintaining at least the required 25 percent public float.\nOther Equity Instruments  \n• The filing reported no outstanding or new warrants, convertibles, Hong Kong depositary receipts, or other share-issuing agreements.\nOverall, the September 2026 return underscores a steady capital structure for SINCO PHARMA, with no equity dilution or treasury share movements and full adherence to Hong Kong listing requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140198649","isCrawlerRequest":true}